If you’ve been exploring medical weight loss options, you’ve likely come across the debate around retatrutide vs tirzepatide. Both medications are making waves in the world of obesity treatment. But they aren’t the same thing — and one of them isn’t even available yet.
This guide breaks down exactly how they differ, what the research shows, and what your real options are today.
What Is Tirzepatide?
Tirzepatide is an FDA-approved medication sold under two brand names:
- Mounjaro — approved for type 2 diabetes (2022)
- Zepbound — approved for chronic weight management (2023)
It works as a dual agonist, meaning it targets two hormone receptors: GLP-1 and GIP. These hormones help your body:
- Feel full faster
- Eat less
- Regulate blood sugar
- Improve metabolism
In the SURMOUNT-1 clinical trial, patients on 15 mg of tirzepatide lost an average of 20.9% of their body weight over 72 weeks. That’s roughly 48 pounds for someone weighing 230 pounds.
Tirzepatide is available right now by prescription. If you’re ready to explore your eligibility, you can learn more about tirzepatide treatment options with a licensed provider.
What Is Retatrutide?
Retatrutide is a newer investigational drug still in clinical trials. It is NOT yet FDA-approved.
It works as a triple agonist — targeting three hormone receptors: GLP-1, GIP, and glucagon. That third target (glucagon) may increase calorie burning and speed up fat breakdown.
In a Phase 2 trial, participants taking 12 mg of retatrutide lost an average of 24.2% of their body weight at 48 weeks. That’s higher than any currently approved weight loss drug.
However, Phase 3 trials are still ongoing. FDA approval is expected no earlier than late 2026 or 2027.
Retatrutide vs Tirzepatide: Head-to-Head Comparison
Here’s a simple breakdown of how the two drugs compare:
| Feature | Tirzepatide | Retatrutide |
|---|---|---|
| FDA Approved | Yes | No (trials ongoing) |
| Mechanism | Dual agonist (GLP-1 + GIP) | Triple agonist (GLP-1 + GIP + Glucagon) |
| Weight Loss (Clinical) | Up to ~21% | Up to ~24% |
| Available by Prescription | Yes | No |
| Injection Frequency | Once weekly | Once weekly (in trials) |
| Long-term Safety Data | Established | Limited |
How Do They Work Differently?
Think of it this way:
- Tirzepatide uses two tools to help you eat less and burn energy.
- Retatrutide adds a third tool — one that may boost your metabolism even further.
The extra glucagon receptor activity in retatrutide may help the body burn more fat. But this also means more potential for side effects, especially in early dose escalation.
A systematic review published in The NNT found that retatrutide (12 mg) achieved a 22% weight reduction from baseline, compared to 18% for tirzepatide — the highest of any agent in the review’s 26 included trials.
Which Drug Has More Side Effects?
Both drugs share similar side effects because they both activate GLP-1 receptors. Common side effects include:
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Stomach discomfort (usually during dose increases)
With retatrutide, the glucagon activation may add some additional effects like increased feelings of warmth or energy. Since long-term safety data is limited, close monitoring is especially important.
Rare but serious risks for both include pancreatitis, gallbladder issues, and possible thyroid concerns. Always discuss your full medical history with a provider before starting either medication.
Real Patient Experience: What Patients Report
One patient at a medical weight loss clinic described her tirzepatide experience:
“By week 12, my appetite had completely changed. I wasn’t obsessing over food the way I used to. I lost 22 pounds in the first three months and kept going from there.”
Retatrutide data from early trial participants shows similarly strong appetite suppression, with some reporting noticeable changes within the first few weeks.
What About Cost and Availability?
Tirzepatide Pricing
Since tirzepatide is FDA-approved and available today, here’s a quick snapshot of costs:
- Brand name (Zepbound): ~$1,086/month list price
- With commercial insurance + savings card: as low as $25/month
- Through telehealth programs: starting around $299–$499/month
At Tirzepatide Medics, medically supervised tirzepatide programs are available with transparent, flexible pricing options designed to make treatment accessible.
Retatrutide Pricing
Retatrutide has no pricing yet — it’s not commercially available. Any website claiming to sell “retatrutide” outside of a clinical trial is selling an unapproved product. Avoid these sources entirely.
Can You Get Retatrutide Now?
Not through a regular prescription. The only legal way to access retatrutide right now is through an FDA-registered clinical trial.
If you want to start a medically supervised weight loss program today, tirzepatide remains the strongest FDA-approved option available. You can schedule a consultation to get started with a licensed provider.
Who Should Choose Tirzepatide Right Now?
You should consider tirzepatide if you:
- Want an FDA-approved, proven option available today
- Need to start treatment now without waiting
- Have type 2 diabetes or weight-related health conditions
- Prefer a medication with years of real-world safety data
Who Should Watch for Retatrutide?
Retatrutide may be worth watching if you:
- Are already on tirzepatide and want to know what’s next
- Are a healthcare provider tracking obesity medicine advances
- Are interested in potentially enrolling in a Phase 3 clinical trial
The Bottom Line on Retatrutide vs Tirzepatide
When comparing retatrutide vs tirzepatide today, tirzepatide wins for one simple reason: it’s available. It’s FDA-approved, backed by years of clinical data, and delivering real results for real people right now.
Retatrutide shows tremendous promise. Its triple-agonist mechanism may eventually make it the gold standard in obesity treatment. But until Phase 3 trials are complete and the FDA reviews the data, it remains an exciting future option — not a current one.
If you’re ready to take a real step toward medical weight loss, access your personalized plan through the Tirzepatide Medics patient portal.
Frequently Asked Questions
Is retatrutide better than tirzepatide for weight loss?
Early trial data show retatrutide may produce slightly higher weight loss, but tirzepatide is FDA-approved and available now, making it the practical choice today.
Can I get retatrutide from my doctor?
No — retatrutide is still in clinical trials and cannot be prescribed by any provider as of 2026.
How much weight can I lose with tirzepatide?
In clinical trials, patients lost up to 20–21% of their body weight over 72 weeks at the highest dose.
Are retatrutide and tirzepatide the same drug?
No — they are different drugs; tirzepatide targets two hormone receptors while retatrutide targets three.
What are the side effects of both drugs?
Both share similar GI side effects like nausea, diarrhea, and vomiting, particularly during the early dose escalation phase.
When will retatrutide be FDA-approved?
FDA approval is expected no earlier than late 2026, pending completion of Phase 3 trials.
Sources
- FDA: Zepbound Approval Information
- NIH/NLM: Tirzepatide — StatPearls
- The NNT: Efficacy of Tirzepatide, Retatrutide and Semaglutide for Weight Loss
- Drugs.com: How Does Retatrutide Compare to Tirzepatide?
